XLO - NASDAQ

Xilio Therapeutics, Inc.

XLO·NASDAQ

$8.46

-0.71%

HealthcareBiotechnology

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.61M

EPS-4.1900

P/E Ratio-21.38

Earnings Date08/13/2026

xlo

Total Debt

Last Annual Value

6.95M

3-Year CAGR

-30%

5-Year CAGR

-20%

10-Year CAGR

-9%

Adjust for Inflation

Xilio Therapeutics, Inc. Competitors Analysis of Total Debt

XLO · NASDAQ

Company	Total Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
Xilio Therapeutics, Inc. NASDAQ:XLO	6.95M	-15.3%	-19.6%	N/A
PDS Biotechnology Corporation NASDAQ:PDSB	5.19B	501.6%	538.2%	79.5%
OnKure Therapeutics, Inc. NASDAQ:OKUR	549.00K	-6.6%	N/A	N/A
Actinium Pharmaceuticals, Inc. AMEX:ATNM	1.57M	-9.4%	38.4%	N/A
Kezar Life Sciences, Inc. NASDAQ:KZR	2.33M	-50.3%	-30.2%	N/A
Aligos Therapeutics, Inc. NASDAQ:ALGS	5.25M	-22.2%	-18.3%	N/A

Xilio Therapeutics, Inc. Fair Value Envelope

XLO · NASDAQ

Our analysis suggests that XLO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.46, this represents a potential HIDDEN relative to our calculated worth for Xilio Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $8.46

Related Guides

Blog Categories

Continue your XLO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.